Press Releases and Events
PRESS RELEASES
Press Release | August 29, 2024
Press Release | August 12, 2024
Crinetics Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | August 8, 2024
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
READ MORE
Press Release | August 8, 2024
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
READ MORE
Press Release | July 10, 2024
Crinetics Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | June 18, 2024
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
READ MORE
Press Release | June 10, 2024
Crinetics Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | June 3, 2024
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
READ MORE
Press Release | June 3, 2024
Crinetics Presents New Data at ENDO 2024 that Increases that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
READ MORE
Press Release | May 30, 2024
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
READ MORE
SIGN UP
WEBCAST
PRESENTATIONTransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
